1.10.2010

Nordic exchanges followed up on an exceptionally strong September with a relatively lacklustre start for October. Bionor pharma, which had been creeping up mysteriously high last few weeks based mainly on commentary earlier on in the summer that Vacc-4x is still effective in HIV after 7-years of injection, sold out a gargantuous 80% on the failure of their aforementioned therapeutic HIV-vaccine candidate Vacc-4x in a phase IIb trial. The trial was a follow-up on the IIa trial seven years ago. The company seizes the development of the product candidate. LifeCycle Pharma’s 25% drop on news that they will call in an extraordinary general meeting to try to raise 450 million Kroner of new capital continued a bloodbath of a day to Nordic biotechnology industry.